A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
Recruiting · Phase 1, Phase 2 · NCT05584670
Conditions: Solid Tumor
At a glance
- Research payments reported, 2025
- $4.1M
- U.S. investigators named
- 7
- Sites paid
- 8
- Planned or actual enrollment
- 542
About the trial
- Sponsor
- Sanofi
- Tested
- SAR445877 (drug), Cetuximab (drug), ADG126 (drug), Bevacizumab (drug), Nivolumab (drug), Ipilimumab (drug)
- Dates
- Started 2022-11-29; completion 2028-06-28
- Results posted
- Not yet
This is a Phase 1/2, open label, multiple cohort study to assess the safety and preliminary efficacy of SAR445877 as a monotherapy or in combination with other anticancer therapies for participants aged at least 18 years with advanced unresectable or metastatic solid tumors. The study will include 2 parts: A dose escalation Part 1: for finding the therapeutic dose(s) of SAR445877 in a monotherapy given every 2 weeks (Q2W) or weekly (QW) and in combination with other anticancer therapies when applicable. A multicohort dose expansion/dose optimization Part 2: for the assessment of safety and preliminary efficacy of SAR445877 in monotherapy and in combination with cetuximab or with next gene…
From ClinicalTrials.gov, last updated 2026-06-23. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $4.1M in research payments for this study in 2025 (122 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Saima Sharif, M.D. Medical Oncology · Iowa City, IA
- Joaquina C. Baranda, MD Medical Oncology · Westwood, KS
- Ammar Sukari, M.D. Medical Oncology · Detroit, MI
- Martin E. Gutierrez, MD Medical Oncology · Hackensack, NJ
- Paul E. Oberstein, MD Medical Oncology · New York, NY
- Khaldoun Almhanna, MD, MPH Hematology & Oncology · Providence, RI
- Aung Naing, MD Internal Medicine · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ut MD Anderson Cancer Center $2.4M
- Hackensack University Medical Center, NJ $735,440
- Rhode Island Hospital, RI $465,507
- Kumc Research Institute,incorporation $348,956
- New York University $63,389
- University of Iowa Hospital & Clinics, IA $50,528
- Karmanos Cancer Center, MI $41,900
- Multiple Doctors $27,583
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.